Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis (MTX01)

This study has been completed.
Sponsor:
Collaborators:
Consultants in Neurology
Biogen
Information provided by:
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
ClinicalTrials.gov Identifier:
NCT00037102
First received: May 15, 2002
Last updated: June 16, 2009
Last verified: November 2003
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: December 2003
  Estimated Primary Completion Date: No date given